Home Healthcare Coherus BioSciences Secured Rights to Commercialize CHS-1420
Coherus BioSciences Secured Rights to Commercialize CHS-1420

Coherus BioSciences Secured Rights to Commercialize CHS-1420

Coherus executed settlement agreements with AbbVie Inc. that provided rights to Coherus to commercialize CHS-1420, according to a report published on March 25, 2019.

Through this agreement, Coherus BioSciences, Inc. will have global, non-exclusive license rights under AbbVie’s intellectual property to commercialize CHS-1420, which is Coherus’ proposed adalimumab (Humira) biosimilar. All pending disputes between both the companies regarding this biosimilar was resolved through this global settlements.

As per the U.S. settlement, license period of Coherus in the U.S. will begin on December 15, 2023. The royalties will be paid to AbbVie by Coherus. The companies have not yet disclosed the financial terms. Denny Lanfear, Chairman, CEO and President of Coherus said, “Biosimilars have an essential role in our healthcare system to restrain cost increases while expanding access for patients. We expect to launch CHS-1420 with our own sales force and deliver significant top-line growth thereafter.”

Coherus has various biosimilar candidates in pipeline for high-value treatments for patients in need, wherein CHS-1420 is one among them. Other pipeline products of the company include Enbrel, Lucentis, and Eylea. Currently, biologics license application for CHS-1420 is being prepared by the company for submission to the U.S. Food and Drug Administration, which is expected to be filed by end of 2019. By the launch of CHS-1420 in the U.S. by late 2023, the company is expected to reach a good position wherein they can effectively leverage the commercial infrastructure it has already deployed for its recent U.S. launch of Udencya (pegfilgrastim-cbqv).

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential.

For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com


Anagha Kulkarni
Anagha Kulkarni,

Anagha Kulkarni
All Posts